ID   KS24
AC   CVCL_E6X7
SY   KS 24; KS-CD80
RX   PubMed=9384677;
RX   PubMed=10359208;
RX   PubMed=10359214;
RX   PubMed=15365776;
CC   Characteristics: Transfection of CD80 has resulted in improved primary T cell activation (PubMed=9384677).
CC   Genetic integration: Method=Transfection; Gene=HGNC; HGNC:1700; CD80.
CC   Genetic integration: Method=Transfection; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_E6X5 ! KS [Human breast carcinoma]
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=9384677;
RA   Guckel B., Lindauer M., Rudy W., Habicht A., Siebels M., Kaul S.,
RA   Bastert G., Meuer S.C., Moebius U.;
RT   "CD80-transfected human breast and ovarian tumor cell lines: improved
RT   immunogenicity and induction of cytolytic CD8+ T lymphocytes.";
RL   Cytokines Mol. Ther. 1:211-221(1995).
//
RX   PubMed=10359208; DOI=10.1038/sj.cgt.7700050;
RA   Guckel B., Meyer G.C., Rudy W., Batrla R., Meuer S.C., Bastert G.,
RA   Wallwiener D., Moebius U.;
RT   "Interleukin-12 requires initial CD80-mediated T-cell activation to
RT   support immune responses toward human breast and ovarian carcinoma.";
RL   Cancer Gene Ther. 6:228-237(1999).
//
RX   PubMed=10359214; DOI=10.1038/sj.cgt.7700054;
RA   Meyer G.C., Batrla R., Rudy W., Meuer S.C., Wallwiener D., Guckel B.,
RA   Moebius U.;
RT   "Potential of CD80-transfected human breast carcinoma cells to induce
RT   peptide-specific T lymphocytes in an allogeneic human
RT   histocompatibility leukocyte antigens (HLA)-A2.1+-matched situation.";
RL   Cancer Gene Ther. 6:282-288(1999).
//
RX   PubMed=15365776; DOI=10.1007/s00262-004-0583-z; PMCID=PMC11034349;
RA   Guckel B., Stumm S., Rentzsch C., Marme A., Mannhardt G.,
RA   Wallwiener D.;
RT   "A CD80-transfected human breast cancer cell variant induces
RT   HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as
RT   well as in vivo.";
RL   Cancer Immunol. Immunother. 54:129-140(2005).
//